These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38964591)

  • 1. Implementation of a North Dakota Opioid Misuse and Overdose Prevention Program in West Virginia.
    Skoy E; Linger R; Eukel H; Bisset S; Frenzel O; Steig J; Strand M; Werremeyer A
    J Am Pharm Assoc (2003); 2024 Jul; ():102152. PubMed ID: 38964591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
    Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
    J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose.
    Skoy E; Frenzel O; Eukel H; Lothspeich E; Steig J; Strand M; Werremeyer A
    Prev Chronic Dis; 2022 Jul; 19():E41. PubMed ID: 35834737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model.
    Strand MA; Eukel H; Frenzel O; Skoy E; Steig J; Werremeyer A
    Res Social Adm Pharm; 2020 Sep; 16(9):1248-1254. PubMed ID: 31812501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the opioid and naloxone education (ONE) program: Program evaluation using the RE-AIM model four years later.
    Strand MA; Frenzel O
    Res Social Adm Pharm; 2024 Jul; 20(7):648-653. PubMed ID: 38627152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.
    Pollini RA; Ozga JE; Joyce R; Xuan Z; Walley AY
    Drug Alcohol Depend; 2022 Feb; 231():109259. PubMed ID: 34998246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of the Pharmacist in Combating the Opioid Crisis: An Update.
    Kosobuski L; O'Donnell C; Koh-Knox Sharp CP; Chen N; Palombi L
    Subst Abuse Rehabil; 2022; 13():127-138. PubMed ID: 36597518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a Pharmacy Follow-Up Program for Dispensed Opioid Medications.
    Skoy E; Frenzel O; Pajunen H; Eukel H
    Int J Environ Res Public Health; 2023 Aug; 20(17):. PubMed ID: 37681768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.
    Rao D; Ford JH; Shiyanbola OO
    Addict Sci Clin Pract; 2024 Apr; 19(1):27. PubMed ID: 38589965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief intervention medication therapy management: Establishment of an opioid misuse intervention model delivered in a community pharmacy.
    Kenney A; Cox N; Bryan MA; Cochran G
    Am J Health Syst Pharm; 2021 Feb; 78(4):310-319. PubMed ID: 33386733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Experience and Satisfaction with Opioid-Related Screening and Intervention in North Dakota Community Pharmacies.
    Lothspeich E; Werremeyer A; Chase S; Huseth-Zosel A
    J Pharm Pract; 2023 Oct; 36(5):1217-1224. PubMed ID: 35704458
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacy on-site overdose protocols and prevention of overdose.
    Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
    Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid risk screening: Program evaluation from the community pharmacists' perspective.
    Frenzel O; Eukel H; Lothspeich E; Skoy E; Steig J; Strand M; Werremeyer A
    J Am Pharm Assoc (2003); 2022; 62(3):859-863.e1. PubMed ID: 34953730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of hepatitis C screening within a pharmacist-managed medication-assisted therapy opioid use disorder protocol program.
    Llayton CK; Harlow CP; Burris JN; Rhodes J
    J Am Pharm Assoc (2003); 2020; 60(6):e307-e311. PubMed ID: 32527703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Implementation of Tech-Check-Tech Programs in North Dakota Pharmacies.
    Halvorson D; Eukel HN; Gilbraith M; Schaper T; Miller DR
    J Pharm Pract; 2023 Oct; 36(5):1102-1107. PubMed ID: 35417659
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.